Beck Mack & Oliver’s Verrica Pharmaceuticals VRCA Stock Holding History

Beck Mack & Oliver’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63.5K	Hold	12,000	–	–	﹤0.01%	192
2025 Q4	$99.7K	Buy	+12,000	New	+$66.5K	﹤0.01%	188
2025 Q3	–	Sell	-7,000	Closed	-$37.1K	–	193
2025 Q2	$37.1K	Hold	7,000	–	–	﹤0.01%	183
2025 Q1	$31K	Hold	7,000	–	–	﹤0.01%	182
2024 Q4	$49K	Hold	7,000	–	–	﹤0.01%	183
2024 Q3	$102K	Buy	7,000 +4,000	+133%	+$180K	﹤0.01%	170
2024 Q2	$219K	Hold	3,000	–	–	﹤0.01%	164
2024 Q1	$178K	Hold	3,000	–	–	﹤0.01%	169
2023 Q4	$220K	Hold	3,000	–	–	0.01%	168
2023 Q3	$117K	Hold	3,000	–	–	﹤0.01%	161
2023 Q2	$173K	Hold	3,000	–	–	﹤0.01%	166
2023 Q1	$195K	Hold	3,000	–	–	0.01%	162
2022 Q4	$82.5K	Hold	3,000	–	–	﹤0.01%	168
2022 Q3	$88K	Hold	3,000	–	–	﹤0.01%	164
2022 Q2	$58K	Buy	3,000 +2,000	+200%	+$101K	﹤0.01%	169
2022 Q1	$81K	Hold	1,000	–	–	﹤0.01%	187
2021 Q4	$92K	Hold	1,000	–	–	﹤0.01%	200
2021 Q3	$125K	Hold	1,000	–	–	﹤0.01%	210
2021 Q2	$113K	Hold	1,000	–	–	﹤0.01%	198
2021 Q1	$152K	Hold	1,000	–	–	﹤0.01%	184
2020 Q4	$115K	Hold	1,000	–	–	﹤0.01%	193
2020 Q3	$77K	Hold	1,000	–	–	﹤0.01%	187
2020 Q2	$110K	Hold	1,000	–	–	﹤0.01%	186
2020 Q1	$109K	Hold	1,000	–	–	﹤0.01%	178
2019 Q4	$159K	Hold	1,000	–	–	0.01%	207
2019 Q3	$148K	Hold	1,000	–	–	0.01%	201
2019 Q2	$116K	Hold	1,000	–	–	﹤0.01%	213
2019 Q1	$108K	Hold	1,000	–	–	﹤0.01%	214
2018 Q4	$82K	Buy	+1,000	New	+$121K	﹤0.01%	212

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beck Mack & Oliver's VRCA Position: Q1 2026 in Review

Beck Mack & Oliver held its Verrica Pharmaceuticals (VRCA) position steady in Q1 2026 at 12,000 shares worth $63.5K. The position accounts for ﹤0.01% of the portfolio, ranked #192.

Beck Mack & Oliver first reported a position in VRCA in Q4 2018 and has held it in 29 quarters since. The position peaked at $220K in Q4 2023. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

Beck Mack & Oliver held 12,000 shares of Verrica Pharmaceuticals worth $63.5K as of Q1 2026.
Beck Mack & Oliver left its Verrica Pharmaceuticals share count unchanged in Q1 2026.
Verrica Pharmaceuticals made up ﹤0.01% of Beck Mack & Oliver's portfolio in Q1 2026, its #192 holding.
Beck Mack & Oliver first reported a position in Verrica Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
Beck Mack & Oliver's Verrica Pharmaceuticals position peaked at $220K in Q4 2023.
39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Beck Mack & Oliver's 13F filing for Q1 2026, filed 12 May 2026.